Adult Trials Open to Accrual

Transcription

1 > Breast > Symptom Management / Survivorship Melisko, Michelle A Registry Study of the Penguin Cold Cap Used for Prevention of Hair Loss in Breast Cancer Patients Receiving Chemotherapy Supportive Care Amy Deluca; Amy.Deluca@ucsf.edu; NCT Miaskowski, Christine Characterization of and for Chemotherapy Neuropathy Supportive Care 1. is an adult >18 years of age 2. has received a platinum compound and/or a taxane 3. has completed a course of CTX 4. has changes in sensation and/or pain in their feet of >3 months duration following the completion of CTX Claudia West; claudia.west@nursing.ucsf.edu; Judy Mastick; judy.mastick@nursing.ucsf.edu; Melissa Mazor; Melissa.Mazor@nursing.ucsf.edu; > Breast > Breast Cancer > Advanced Breast Cancer > ER NCT Rugo, Hope Reversing Hormone Resistance in Advanced Breast Cancer with Pazopanib 1. Subjects must have measurable or evaluable disease. Disease sites that are evaluable for progression but not measurable per RECIST guidelines include: Bone lesions, Previously irradiated lesions, & Cutaneous manifestations (non- discreet lesions only) years of age or older. 3. Histologically or cytologically confirmed estrogen receptor (ER) and/or progesterone receptor (PgR) positive carcinoma of the breast with unresectable, locally advanced and/or metastatic (AJCC Stage IV) disease. 4. Subjects must have received prior hormonal therapy for the treatment of breast cancer Amy Deluca; Amy.Deluca@ucsf.edu; NCT Munster, Pamela A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer Age: 18+ Postmenopausal, Estrogen- receptor positive breast cancer Alyson Cockerill; Alyson.Cockerill@ucsf.edu; Interventional Trials Open to Accrual as of 10/15/15 Page 1 of 56

2 > Breast > Breast Cancer > Advanced Breast Cancer > Triple Negative NCT Melisko, Michelle A Randomized Multi- Center Phase II Study of CDX- 011 (CR011- vcmmae) in Patients with Metastatic, GPNMB Over- Expressing, Triple Negative Breast Cancer Age: Diagnosed with metastatic (i.e., cancer that has spread) triple negative (does not have hormone receptors ER or PR or HER2) breast cancer. 2. Breast cancer tumor confirmed to express gpnmb. This will be determined by submitting a tissue sample from the advanced (locally advanced/recurrent or metastatic) disease setting to a central laboratory for analysis. 3. Received no more than two prior chemotherapy treatments for advanced (locally advanced/recurrent or metastatic) breast cancer. 4. Prior chemotherapy treatment must have contained an anthracycline (e.g. doxorubicin or Doxil) and a taxane (eg: Taxol). 5. Breast cancer must be resistant or intolerant to treatment containing taxane (e.g. Taxol). Call us at > Breast > Breast Cancer > Advanced Breast Cancer > Brain Metastases/leptomeningeal dz NCT Melisko, Michelle A Phase II Trial of HKI- 272 (Neratinib) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)- Positive Breast Cancer and Brain Metastases Age: 18+ * Patients (men or women) must have histologically or cytologically confirmed invasive breast cancer, with metastatic disease. Patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis by physical exam or radiologic study. * Invasive primary tumor or metastatic tissue confirmation of HER2- positive status * No prior therapy with neratinib is allowed Amy Deluca; Amy.Deluca@ucsf.edu; NCT Melisko, Michelle Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the of Leptomeningeal Metastases in HER2 Positive Breast Cancer Age: 18+ * HER2 positive (IHC 3+ and/or FISH positive) breast cancer patients with leptomeningeal metastases by MRI or CSF (if MRI is negative). Amy Deluca; Amy.Deluca@ucsf.edu; Interventional Trials Open to Accrual as of 10/15/15 Page 2 of 56

3 > Breast > Breast Cancer > Advanced Breast Cancer > Non- Specific NCT Rugo, Hope Phase II Study of MGAH22 (Fc- optimized Chimeric Anti- HER2 Monoclonal Antibody) in Patients with Relapsed or Refractory MBC whose Tumors Express HER2 at the 2+ Level by Immunohisotochemistry and Lack Evidence of HER2 Gene Amplification by FISH * Histologically or cytologically confirmed invasive carcinoma of the breast * Evidence of progression of disease during or following at least two prior systemic therapies for advanced (unresectable locoregional or metastatic) disease Amy Deluca; Amy.Deluca@ucsf.edu; > Breast > Breast Cancer > Advanced Breast Cancer > Early Phase NCT Rugo, Hope A Phase 1b/ll Study of Eribulin in Combination with Cyclophosphamide in Patients with Solid Tumor Malignancies 1. Phase Ib: Patient must have histologically or cytologically documented solid tumor malignancies. Phase II: Patients must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast. Karla Sarantopulos; Karla.Sarantopulos@ucsfmedctr.or g; NCT Rugo, Hope Enhancing Efficacy of Chemotherapy in Triple Age: 18+ Negative/Basal- Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II study of PLX 3397 and Eribulin in Patients with Metastatic Breast Cancer * Pathologically confirmed diagnosis of breast cancer with documented progressive disease. * At least one prior chemotherapy regimen for metastatic breast cancer. Amanda DeSon; DeSonA@cc.ucsf.edu; Mike Pelayo; pelayom@ucsf.edu; > Breast > Breast Cancer > Early Stage Breast Cancer > In Situ > Pre- Surgery (Neoadjuvant) CALGB NCT Esserman, Laura Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma In Situ (DCIS) * Pathologic confirmation of ductal carcinoma in situ (DCIS) without invasive Sarah Davis; cancer of the female breast with diagnosis rendered on core biopsy only sarah.davis@ucsfmedctr.org; 415- * DCIS must express estrogen receptor, as determined by immunohistochemical methods on the diagnostic pathology sample Interventional Trials Open to Accrual as of 10/15/15 Page 3 of 56

4 NCT Chien, Jo I- SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And molecular Analysis) * Histologically confirmed invasive cancer of the breast Julia Lyandres; * Clinically or radiologically measureable disease in the breast after diagnostic julia.lyandres@ucsfmedctr.org; biopsy, defined as longest diameter greater than or equal to 25 mm (2.5cm) * No prior cytotoxic regimens are allowed for this malignancy. Patients may Sarah Davis; not have had prior chemotherapy or prior radiation therapy to the ipsilateral sarah.davis@ucsfmedctr.org; 415- breast for this malignancy. Prior bis- phosphonate therapy is allowed * Willing to undergo core biopsy of the primary breast lesion to assess baseline biomarkers * Non- pregnant and non- lactating * No ferromagnetic prostheses. Patients who have metallic surgical implants that are not compatible with an MRI machine are not eligible. * Eligible tumors must meet one of the following criteria: Stage II or III, or T4, any N, M0, including clinical or pathologic inflammatory cancer or Regional Stage IV, where supraclavicular lymph nodes are the only sites metastasis * Any tumor ER/PgR status, any HER- 2/neu status as measured by local hospital pathology laboratory and meets any tumor assay profile described in protocol section 4.1.2F * Normal organ and marrow function: Leukocytes >/= 3000/uL, Absolute neutrophil count >/= 1500/uL, Platelets >/= 100,000/uL, Total bilirubin within normal institutional limits, unless patient has Gilbert's disease, for which bilirubin must be </= 2.0 x ULN, AST(SGOT)/ALT (SGPT) </= 1.5 x institutional ULN, creatinine < 1.5 x institutional ULN * No uncontrolled or severe cardiac disease. Baseline ejection fraction (by nuclear imaging or echocardiography) must by >/= 50% * No clinical or imaging evidence of distant metastases by PA and Lateral CXR, Radionuclide Bone scan, and LFTs including total bilirubin, ALT, AST, and alkaline phosphatase * Tumor assay profile must include one of the following: MammaPrint High, any ER status, any HER2 status, or MammaPrint Low, ER negative (<5%), any HER2 status, or MammaPrint Low, ER positive, HER2/neu positive by any one of the three methods used (IHC, FISH, TargetPrint) > Gastrointestinal > Pancreatic Cancer NCT Miaskowski, Christine Characterization of and for Chemotherapy Neuropathy Supportive Care 1. is an adult >18 years of age 2. has received a platinum compound and/or a taxane 3. has completed a course of CTX 4. has changes in sensation and/or pain in their feet of >3 months duration following the completion of CTX Claudia West; claudia.west@nursing.ucsf.edu; Judy Mastick; judy.mastick@nursing.ucsf.edu; Melissa Mazor; Melissa.Mazor@nursing.ucsf.edu; Interventional Trials Open to Accrual as of 10/15/15 Page 4 of 56

5 > Gastrointestinal > Colon Cancer NCT Miaskowski, Christine Characterization of and for Chemotherapy Neuropathy Supportive Care 1. is an adult >18 years of age 2. has received a platinum compound and/or a taxane 3. has completed a course of CTX 4. has changes in sensation and/or pain in their feet of >3 months duration following the completion of CTX Claudia West; claudia.west@nursing.ucsf.edu; Judy Mastick; judy.mastick@nursing.ucsf.edu; Melissa Mazor; Melissa.Mazor@nursing.ucsf.edu; > Gastrointestinal > Rectal Cancer NCT Miaskowski, Christine Characterization of and for Chemotherapy Neuropathy Supportive Care 1. is an adult >18 years of age 2. has received a platinum compound and/or a taxane 3. has completed a course of CTX 4. has changes in sensation and/or pain in their feet of >3 months duration following the completion of CTX Claudia West; claudia.west@nursing.ucsf.edu; Judy Mastick; judy.mastick@nursing.ucsf.edu; Melissa Mazor; Melissa.Mazor@nursing.ucsf.edu; > Gastrointestinal > Anal Cancer NCT Miaskowski, Christine Characterization of and for Chemotherapy Neuropathy Supportive Care 1. is an adult >18 years of age 2. has received a platinum compound and/or a taxane 3. has completed a course of CTX 4. has changes in sensation and/or pain in their feet of >3 months duration following the completion of CTX Claudia West; claudia.west@nursing.ucsf.edu; Judy Mastick; judy.mastick@nursing.ucsf.edu; Melissa Mazor; Melissa.Mazor@nursing.ucsf.edu; Interventional Trials Open to Accrual as of 10/15/15 Page 5 of 56

6 > Gastrointestinal > Hepatocellular Carcinoma (liver cancer) RTOG NCT Chang, Albert Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma Romobia Hutchinson; > Gastrointestinal > Anal Cancer > Prevention NCT Palefsky, Joel A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine, in 16- to 26- Year- Old Men and 16- to 26- Year- Old Women Prevention Age: * Has never had Pap testing (cervical or anal) or has only had normal Pap test results Fred Fishman; Fred.Fishman@ucsf.edu; AMC- A01 NCT Palefsky, Joel ANCHOR Study: Anal Cancer Prevention Anal Cancer /HSIL Outcomes Research Study Prevention Age: 35+ Abigail Arons; * HIV- 1 infection, as documented by any federally approved, licensed HIV test Abigail.Arons@ucsf.edu; performed in conjunction with screening * No history of treatment or removal of HSIL * No history of anal cancer or signs of anal cancer at baseline, and no history of penile, vulvar, vaginal or cervical cancer Interventional Trials Open to Accrual as of 10/15/15 Page 6 of 56

7 > Gastrointestinal > Colon Cancer > Resectable > Adjuvant (after surgery) CALGB NCT Venook, Alan A Phase III Trial of 6 versus 12 s of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer * Histologically confirmed adenocarcinoma of the colon - Stage III disease - Gross inferior (caudal) margin of the primary tumor must be >/= 12 cm from the anal verge - - No rectal cancer - Synchronous colon cancers allowed - - No synchronous colon and rectal primary tumors * Completely resected tumor - Patients with adherent to adjacent structures, en bloc R_o resected tumor, must have it documented in the operative report * At least 1 pathologically confirmed positive lymph node OR the AJCC v. 7 designation of N1C defined as tumor deposit(s) in the subserosa, mesentery, nonperitonealized pericolic, or perirectal tissues without regional lymph node metastases * No evidence of residual involved lymph node disease or metastatic disease Sharvina Ziyeh; ZiyehS@ucsf.edu; > Gastrointestinal > Rectal Cancer > Resectable > Neoadjuvant (before surgery) CTSU- NCCTG- N1048 NCT Venook, Alan A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision Age: 18+ * Diagnosis of rectal adenocarcinoma * For this patient, the standard treatment recommendation in the absence of a clinical trial would be combined- modality, neoadjuvant chemoradiation followed by curative- intent surgical resection * No chemotherapy within 5 years prior to registration Sharvina Ziyeh; ZiyehS@ucsf.edu; Interventional Trials Open to Accrual as of 10/15/15 Page 7 of 56

8 CALGB NCT Venook, Alan PET Scan- Directed Combined Modality Therapy in Esophageal Cancer * Surgically resectable, histologically confirmed esophageal adenocarcinoma, Adrienne Brenner; including Siewert gastroesophageal (GE) junction adenocarcinomas Types 1 and BrennerA@cc.ucsf.edu; 2 * No evidence of distant metastases (as determined by EUS or PET/CT) * Patients with cervical, supraclavicular, or other nodal disease that is either not included in the radiation field or is not able to be resected at the time of esophagectomy are not eligible * Patients must have detectable fluorine- 18- labeled deoxyglucose (FDG) uptake on baseline PET/CT scan of primary tumor * HER 2- positive patients who are eligible for the RTOG study are not eligible for CALGB > Gastrointestinal > Hepatocellular Carcinoma (liver cancer) > Metastatic/Advanced > First- Line CALGB NCT Venook, Alan Phase III Study of Sorafenib plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) * Pathologically or cytologically proven hepatocellular carcinoma (HCC) - No known mixed histology or fibrolamellar variant * Locally advanced or metastatic disease - Patients with locally advanced disease must have disease deemed to be unresectable OR not be eligible for transplantation * Measurable disease, defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >/= 2 cm with conventional techniques or as >/= 1 cm with spiral CT scan * Child- Pugh score A * No known CNS tumors, including brain metastases Jennifer Luan; jennifer.luan@ucsf.edu; Lindsey Alami; Lindsey.Watt@ucsf.edu; NCT Kelley, Katie Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Age: *Patients must have histologically diagnosed AJCC stage II, III, or IV HCC not eligible for curative resection, transplantation, or ablative therapies Ryan Mcwhirter; Ryan.McWhirter@ucsf.edu; NCT Kelley, Katie Phase 2 Study of LY in Patients with Hepatocellular Carcinoma * Have histological evidence of a diagnosis of HCC not amenable to curative surgery * Serum alpha fetoprotein greater than or equal to 1.5 Upper Limits of Normal * Child- Pugh Stage A * Have the presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). A lesion that has been previously treated by local therapy will qualify as a measurable or evaluable lesion if there was demonstrable progression following locoregional therapy * Have received sorafenib and have progressed or were intolerant to sorafenib or are ineligible for sorafenib treatment Interventional Trials Open to Accrual as of 10/15/15 Page 8 of 56

9 14455 NCT Ko, Andrew A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination with Allogeneic GM- CSF Transfected Pancreatic Tumor Vaccine (GVAX) in the of Metastatic Pancreatic Cancer (NCI Protocol #9478) Age: 18+ * Documented adenocarcinoma of the pancreas > Gastrointestinal > Hepatocellular Carcinoma (liver cancer) > Metastatic/Advanced > Second- Line and Beyond NCT Kelley, Katie A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) in Subjects with Hepatocellular Carcinoma who have Received Prior Sorafenib Age: 18+ * Histological or cytological diagnosis of Hepatocellular Carcinoma * Received prior sorafenib > Gastrointestinal > Pancreatic Cancer > Resectable > Adjuvant (after surgery) NCT Ko, Andrew A Phase 3, Multicenter, Open- label, Randomized Study of nab- Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma Age: 18+ Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1). Subjects with neuroendocrine (and mixed type) tumors are excluded. Interventional Trials Open to Accrual as of 10/15/15 Page 9 of 56

10 CALGB NCT Venook, Alan A Phase III Trial of 6 versus 12 s of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer * Histologically confirmed adenocarcinoma of the colon - Stage III disease - Gross inferior (caudal) margin of the primary tumor must be >/= 12 cm from the anal verge - - No rectal cancer - Synchronous colon cancers allowed - - No synchronous colon and rectal primary tumors * Completely resected tumor - Patients with adherent to adjacent structures, en bloc R_o resected tumor, must have it documented in the operative report * At least 1 pathologically confirmed positive lymph node OR the AJCC v. 7 designation of N1C defined as tumor deposit(s) in the subserosa, mesentery, nonperitonealized pericolic, or perirectal tissues without regional lymph node metastases * No evidence of residual involved lymph node disease or metastatic disease Sharvina Ziyeh; ZiyehS@ucsf.edu; > Gastrointestinal > Colon Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic) > Second- Line and Beyond NCT Fidelman, Nicholas A Phase III Trial Evaluating TheraSphere in Patients with mcrc of the Liver who have Failed First Line Chemotherapy Age: 18+ * Colorectal cancer with metastases progressed after first line treatment Curt Johanson; Curt.Johanson@ucsf.edu; NCT Ko, Andrew A Phase 2B, Randomized, Controlled, Multicenter, Open- Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS- 207 Compared to Chemotherapy or to CRS- 207 Alone in Adults with Previously- Treated Metastatic Pancreatic Adenocarcinoma Interventional Trials Open to Accrual as of 10/15/15 Page 10 of 56

11 15454 NCT Ko, Andrew A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS- 207 with or without Nivolumab in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma NCT Ko, Andrew Pilot Study of Autologous T- cells Redirected to Mesothelin and CD19 with a Chimeric Antigen Receptor in Patients with Metastatic Pancreatic Cancer NCT Kelley, Katie A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or Other FGFR Genetic Alterations who Failed or are Intolerant to Platinum- based Chemotherapy NCT Ko, Andrew A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5- Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE- 059) Interventional Trials Open to Accrual as of 10/15/15 Page 11 of 56

12 > Gastrointestinal > Neuroendocrine Tumors (NET) > Well- Differentiated Neuroendocrine Tumor > Pancreatic NET > Resectable CTSU- E2212 NCT Bergsland, Emily A Randomized, Double- Blinded, Placebo- Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver Age: 18+ * Patients must have histologically or pathologically confirmed metastatic low or intermediate grade pancreatic neuroendocrine tumor(s) to the liver > Gastrointestinal > Colon Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic) > Second- Line and Beyond > K- ras wild- type NCT Atreya, Chloe An Open- Label, Three- Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK , BRAF Inhibitor GSK and the anti- EGFR Antibody Panitumumab in Combination in Subjects with BRAF- mutation V600E Positive Colorectal Cancer Age: 18+ * Confirmed diagnosis of advanced or metastatic BRAF V600E or V600K mutation positive colorectal cancer (CRC). Jennifer Luan; jennifer.luan@ucsf.edu; ALLIANCE- S1406 NCT Atreya, Chloe Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Interventional Trials Open to Accrual as of 10/15/15 Page 12 of 56

13 > Gastrointestinal > Neuroendocrine Tumors (NET) > Well- Differentiated Neuroendocrine Tumor > Carcinoid > Metastatic / Unresectable > Systemic Therapy NCT Bergsland, Emily A Phase 3, Randomized, Placebo- Controlled, Parallel- Group, Multicenter, Double- Blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy Age: 18+ Ariceli Alfaro; * Histopathologically- confirmed, well- differentiated metastatic neuroendocrine Ariceli.Alfaro@ucsf.edu; tumor * Documented history of carcinoid syndrome and currently experiencing 4 bowel movements per day during the Run- in period * Currently receiving stable- dose somatostatin analog (SSA) therapy CTSU- E2211 NCT Bergsland, Emily A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors Age: 18+ * Histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor, excluding small cell carcinoma * Must not have received prior temozolomide, dacarbazine (DTIC), or capecitabine, or 5- FU (fluorouracil) therapy ALLIANCE- A NCT Bergsland, Emily Prospective Randomized Phase II Trial of Pazopanib (NSC #737754, IND #75648) versus Placebo in Patients with Progressive Carcinoid Tumors Age: 18+ *Low- or intermediate- grade neuroendocrine carcinoma * Locall unresectable or metastatic carcinoid tumors * No prior treatment with an inhibitor of vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR) Julie Sudduth- Klinger; Julie.Sudduth- Klinger@ucsf.edu; > Genitourinary > Prostate Cancer NCT Chang, Albert Phase 2 Study of 11C- and 18F- Choline Diagnostic PET/MR imaging in Patients with Unfavorable Intermediate to High- Risk Prostate Cancer Christopher Sotto; Christopher.sotto@mrsc.ucsf.edu ; Interventional Trials Open to Accrual as of 10/15/15 Page 13 of 56

14 > Genitourinary > Prostate Cancer > Localized with Radiation RTOG NCT Roach, Mack Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole- Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial * Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate- to high- risk for recurrence * Clinically negative lymph nodes as established by imaging * No evidence of bone metastases (M0) on bone scan Romobia Hutchinson; Romobia.Hutchinson@ucsf.edu; > Genitourinary > Bladder Cancer > Advanced NCT Fong, Lawrence A Phase III Randomized Clinical Trial of Pembrolizumab (MK- 3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer > Genitourinary > Prostate Cancer > Rising PSA After Local NCT Aggarwal, Rahul The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer Age: 18+ * Male * Histologically proven adenocarcinoma of the prostate * No history of seizures or medical conditions which may lower seizure threshold Rebecca Cook; Rebecca.Cook@ucsf.edu; Interventional Trials Open to Accrual as of 10/15/15 Page 14 of 56

15 NCT Aggarwal, Rahul Hedgehog Inhibition as a Non- Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse Age: Histologic confirmation of adenocarcinoma of the prostate 2. Biochemically relapsed disease with a rising PSA on at least two consecutive measurements at least two weeks apart after prior definitive local therapy (radical prostatectomy, external beam radiation, or brachytherapy) or combination of radical prostatectomy and radiotherapy (RT) with curative intent 3. Prior primary or salvage radiation or not a candidate for salvage radiation due to patient preference or clinical assessment based upon disease characteristics and/or patient co- morbidities NCT Fong, Lawrence Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (ptvg- HP) versus GM- CSF Adjuvant in Patients with Non- Metastatic Prostate Cancer * Histologic diagnosis of adenocarcinoma of the prostate * Completion of local therapy by surgery and/or ablative radiation therapy at least 3 months prior to entry, with removal or ablation of all visible disease, including seminal vesical and/or local lymph node involvement * Rising prostate specific antigen (PSA) levels without scan evidence of metastatic disease Kathryn Koepfgen; kkoepfgen@medicine.ucsf.edu; Rebecca Cook; Rebecca.Cook@ucsf.edu; > Genitourinary > Prostate Cancer > Metastatic Disease: Hormone Sensitive NCT Aggarwal, Rahul A Multidisciplinary Team- Based Approach to Mitigate the Impact of Androgen Deprivation Therapy in Prostate Cancer: A Randomized Phase 2 Study Supportive Care > Genitourinary > Prostate Cancer > Castration Resistant PC (CRPC) Without Metastases NCT Small, Eric A Multicenter, Randomized, Double- Blind, Placebo- Controlled, Phase III Study of ARN- 509 in Men with Non- Metastatic (M0) Castration- Resistant Prostate Cancer Age: 18+ * Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features, with high risk for development of metastases * Castration- resistant prostate cancer demonstrated during continuous androgen deprivation therapy/post orchiectomy Call us at Interventional Trials Open to Accrual as of 10/15/15 Page 15 of 56

16 > Genitourinary > Prostate Cancer > Castration Resistant PC (CRPC) With Metastases No Prior Chemotherapy NCT Fong, Lawrence A Randomized Phase 2 Trial of Immediate versus Delayed Anti- CTLA- 4 Blockade Following Sipuleucel- T for Prostate Cancer Immunotherapy Age: 18+ * Metastatic prostate adenocarcinoma * Progressive disease after androgen deprivation Call us at ALLIANCE- A NCT Friedlander, Terence Phase III Trial of Enzalutamide (NSC # ) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer Call us at NCT Ryan, Charles Phase II Single Agent Study of Selinexor (KPT- 330) in Patients with Metastatic Castration Resistant Prostate Cancer (mcrpc) and Prior Therapy with Abiraterone and/or Enzalutamide Age: 18+ * Histologically confirmed adenocarcinoma of the prostate. * See ClinicalTrials.Gov for more eligibility criteria Call us at NCT Friedlander, Terence A Drug- Drug Interaction, Safety and Efficacy Study With JNJ (ARN- 509) and Abiraterone Acetate in Subjects with Metastatic Castration- Resistant Prostate Cancer Age: 18+ * Histologically or cytologically confirmed adenocarcinoma of the prostate * Documentation of metastatic disease * Prostate cancer progression * Surgically or medically castrated, with testosterone levels of < 50 ng/dl (< 1.7 nm) Call us at Interventional Trials Open to Accrual as of 10/15/15 Page 16 of 56

17 > Genitourinary > Prostate Cancer > Castration Resistant PC (CRPC) With Metastases Chemotherapy NCT Aggarwal, Rahul A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients with Metastatic Castration- Resistant Prostate Cancer and no Prior Chemotherapy 1. Histologically confirmed adenocarcinoma of the prostate. 2. Progressive metastatic prostate cancer (positive bone scan or measurable disease) despite castrate levels of testosterone (either from orchiectomy or LHRH agonist therapy). 3. Patients may have either non- measurable disease OR measurable disease 4. All patients must have a PSA >/= 2 ng/ml. 5. Progressive disease based on any one of the following: transaxial imaging; a rise in PSA; radionuclide bone scan *Patients whose sole manifestation of progression is an increase in disease- related symptoms are not eligible. Ryan Courtin; CourtinR@cc.ucsf.edu; > Genitourinary > Renal Cell Carcinoma > Surgical or Adjuvant > Adjuvant CTSU- S0931 NCT Meng, Maxwell EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study Age: 18+ * Renal cell carcinoma * Have undergone a full surgical resection Imelda Tenggara; Imelda.Tenggara@ucsf.edu; > Genitourinary > Bladder Cancer > Surgical or Adjuvant > Adjuvant (after surgery) RTOG NCT Chang, Albert A Phase II Protocol for Patients with Stage T1 Age: 18+ Bladder Cancer to Evaluate Selective Bladder Preserving by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re- Staging * Carcinoma of the bladder, diagnosed within the past 10 weeks * No evidence of distant metastases Romobia Hutchinson; Romobia.Hutchinson@ucsf.edu; Interventional Trials Open to Accrual as of 10/15/15 Page 17 of 56

18 > Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal NCT Miaskowski, Christine Characterization of and for Chemotherapy Neuropathy Supportive Care 1. is an adult >18 years of age 2. has received a platinum compound and/or a taxane 3. has completed a course of CTX 4. has changes in sensation and/or pain in their feet of >3 months duration following the completion of CTX Claudia West; claudia.west@nursing.ucsf.edu; Judy Mastick; judy.mastick@nursing.ucsf.edu; Melissa Mazor; Melissa.Mazor@nursing.ucsf.edu; > Gynecological > Corpus/Endometrial NCT Miaskowski, Christine Characterization of and for Chemotherapy Neuropathy Supportive Care 1. is an adult >18 years of age 2. has received a platinum compound and/or a taxane 3. has completed a course of CTX 4. has changes in sensation and/or pain in their feet of >3 months duration following the completion of CTX Claudia West; claudia.west@nursing.ucsf.edu; Judy Mastick; judy.mastick@nursing.ucsf.edu; Melissa Mazor; Melissa.Mazor@nursing.ucsf.edu; > Gynecological > Cervix > Primary NCT Miaskowski, Christine Characterization of and for Chemotherapy Neuropathy Supportive Care 1. is an adult >18 years of age 2. has received a platinum compound and/or a taxane 3. has completed a course of CTX 4. has changes in sensation and/or pain in their feet of >3 months duration following the completion of CTX Claudia West; claudia.west@nursing.ucsf.edu; Judy Mastick; judy.mastick@nursing.ucsf.edu; Melissa Mazor; Melissa.Mazor@nursing.ucsf.edu; Interventional Trials Open to Accrual as of 10/15/15 Page 18 of 56

19 > Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > Progressive/Recurrent > Platinum Sensitive > More than one prior treatment NCT Chen, Lee- may A Multicenter, Randomized, Double- Blind, Placebo- Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum- Based Chemotherapy in Patients with Platinum- Sensitive, High- Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Age 18+ * Confirmed diagnosis of high- grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer. * Received 2 prior platinum- based treatment regimens. * Received no more than 1 non- platinum regimen. * Must have had at least a 6- month disease- free period following prior treatment with platinum- based chemotherapy and achieved a response. * Have sufficient archival tumor tissue for analysis. Paul Watkins; Paul.Watkins@ucsf.edu; > Head and Neck > Thyroid RTOG NCT Quivey, Jeanne A Randomized Phase II Study of Concurrent IMRT, Paclitaxel and Pazopanib (NSC /Placebo), for the of Anaplastic Thyroid Cancer * Pathologically (histologically or cytologically) proven diagnosis of anaplastic thyroid cancer (a diagnosis that is noted to be "consistent with anaplastic thyroid cancer" with the presence of a thyroid mass is acceptable) * If there was a total or partial thyroidectomy completed within 3 months of enrollment, the surgical specimen must show the area of anaplastic thyroid cancer to be at least 1 cm in greatest dimension * No known brain metastases Romobia Hutchinson; Romobia.Hutchinson@ucsf.edu; > Head and Neck > Symptom Management NCT Yom, Sue A Study Monitoring Quality of Life and Correlative Biomarkers of Mucositis in a Randomized Trial of a Personalized Sterile Humidification Device for Head and Neck Cancer Patients Undergoing Radiation Therapy Supportive Care Priyanka Ghosh; Priyanka.Ghosh@ucsf.edu; Interventional Trials Open to Accrual as of 10/15/15 Page 19 of 56

20 > Head and Neck > Nasopharyngeal CTSU- NRG- HN001 NCT Yom, Sue Randomized Phase II and Phase III Studies of Individualized for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) Age: 18+ Stage II- IVB disease with no evidence of distant metastasis, Romobia Hutchinson; > Head and Neck > Basal Cell Carcinoma > Locally Advanced NCT Yom, Sue A Phase II Study of Radiation Therapy and Vismodegib,for the of Locally Advanced Basal Cell Carcinoma of the Head and Neck > Head and Neck > Squamous Cell > Oropharyngeal NCT Algazi, Alain A Phase II, Randomized, Open- Label, Multi- Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Interventional Trials Open to Accrual as of 10/15/15 Page 20 of 56

21 15203 NCT Algazi, Alain A Phase 1 Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination with Tremelimumab or Tremelimumab Alone in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck > Head and Neck > Squamous Cell > Metastatic > All others NCT Munster, Pamela A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open- Label Study of BYL719 in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Age: 18+ Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Alyson Cockerill; Alyson.Cockerill@ucsf.edu; NCT Algazi, Alain A Phase II, Randomized, Open- Label, Multi- Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Interventional Trials Open to Accrual as of 10/15/15 Page 21 of 56

22 15203 NCT Algazi, Alain A Phase 1 Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination with Tremelimumab or Tremelimumab Alone in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck > Head and Neck > Squamous Cell > Locoregional > Relapsed NCT Algazi, Alain A Phase 1 Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination with Tremelimumab or Tremelimumab Alone in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Interventional Trials Open to Accrual as of 10/15/15 Page 22 of 56

23 > Head and Neck > Squamous Cell > Locoregional > Previously Untreated > Post Operative RTOG NCT Yom, Sue A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally- Advanced Resected Head and Neck Cancer * Histologically confirmed squamous cell carcinoma (including variants, such as Romobia Hutchinson; verrucous carcinoma, spindle cell carcinoma, or carcinoma not otherwise Romobia.Hutchinson@ucsf.edu; specified) of the head and neck, including the following subtypes:oral cavity, Oropharynx, or Larynx. * Clinical stage T1, N1-2, M0 OR T2-3, N0-2, M0 disease based on the following diagnostic workup within the past 8 weeks: General history and physical examination by a Radiation Oncologist and/or Medical Oncologist; Chest x- ray or chest CT scan (with or without contrast) or chest CT/PET scan (with or without contrast) * Must have undergone gross total resection of the primary tumor with curative intent within the past 7 weeks with surgical pathology demonstrating >/= 1 of the following criteria for "intermediate" risk of recurrence: Perineural invasion; Lymphovascular invasion; Single lymph node > 3 cm or >/= 2 lymph nodes (all < 6 cm) (no extracapsular extension); Close margin(s) of resection, defined as cancer extending to within 5 mm of a surgical margin, and/or an initially focally positive margin that is subsequently superseded by intraoperative negative margins (similarly, patients whose tumors had focally positive margins in the main specimen but negative margins from re- excised samples in the region of the positive margin are eligible); T3 or microscopic T4a primary tumor - - No gross T4a or T4b tumor (gross T4 refers to unequivocal findings on preoperative physical exam and/or radiologic studies [e.g., tongue fixation, tumor destruction through thyroid cartilage] and/or macroscopic tumor evaluation by the surgeon and/or pathologist prior to tissue sample processing) - T2 oral cavity cancer with > 5 mm depth of invasion * No positive margin(s) (defined as tumor present at the cut or inked edge of the tumor), nodal extracapsular extension, and/or gross residual disease after surgery * Ineligible for an RTOG "high risk" head and neck cancer clinical trial (e.g., RTOG 0619). RTOG NCT Yom, Sue Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High- Risk Squamous Cell Cancer of the Head and Neck Age 18+ * Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 49 days of registration * Patients must have undergone gross total surgical resection of high- risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 49 days prior to registration * Patients must have at least 1 of the following high- risk pathologic features: extracapsular nodal extension or invasive cancer seen within 3 mm of the primary tumor resection margins * Pathologic stage III or IV head and neck squamous cell carcinoma (HNSCC), including no distant metastases Romobia Hutchinson; Romobia.Hutchinson@ucsf.edu; Interventional Trials Open to Accrual as of 10/15/15 Page 23 of 56

24 > Head and Neck > Squamous Cell > Locoregional > Previously Untreated > Definitive Radio Therapy (RT) RTOG NCT Yom, Sue A Phase II, Randomized, Double- Blind, Placebo- Controlled Study of Lapatinib (TYKERB ) for Non- HPV Locally Advanced Head and Neck Cancer with Concurrent Chemoradiation Age: 18+ Squamous Cell Cancer of the oropharynx, hypopharynx or larynx Romobia Hutchinson; Romobia.Hutchinson@ucsf.edu; > Malignant Hematology > Blood and Marrow Transplant (BMT) NCT Logan, Aaron A Multi- Center, Randomized, Double- Blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of CSJ148 Compared to Placebo to Prevent Human Cytomegalovirus (HCMV) Replication in Stem Cell Transplant Patients > Malignant Hematology > Chronic Myeloid Leukemia (CML) NCT Shah, Neil Open- Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia (CP- CML) with Stable Complete Molecular Response (CMR) DASFREE Age: 18+ * Men and women diagnosed with CP- CML, on treatment with Dasatinib for a minimum of 2 years at the time of enrollment and in Dasatinib - induced complete molecular remission ongoing for at least 1 year prior to study entry Interventional Trials Open to Accrual as of 10/15/15 Page 24 of 56

25 > Malignant Hematology > Non- Hodgkin Lymphoma (NHL) NCT Andreadis, Charalambos A Phase 2b Open- Label, Randomized Two- Arm Study Comparing High and Low Doses of Selinexor (KPT- 330) in Patients with Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) CALGB NCT Rubenstein, James A Randomized Phase II Trial of Myeloablative Versus Non- Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B- cell Lymphoma Age * Diagnosis of primary central nervous system (CNS) diffuse large B- cell lymphoma * No evidence or history of non- Hodgkin lymphoma (NHL) outside of CNS * No HIV, Hepatitis B, or Hepatitis C Geraldine Pelle- Day; Geraldine.pelle- day@ucsf.edu; > Malignant Hematology > Phase I > Acute Leukemia NCT Andreadis, Charalambos A Phase I Dose Finding and Proof- of- Concept Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Combination with Standard Dose Cytarabine and Daunorubicin for Older Patients with Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome * Untreated histologically confirmed acute myeloid leukemia OR advanced myelodysplastic syndrome (INT- 2 or High risk) not previously treated with anthracycline- based chemotherapy OR a therapy- related myeloid neoplasm * Male or female aged>/= 60 years Geraldine Pelle- Day; Geraldine.pelle- day@ucsf.edu; Interventional Trials Open to Accrual as of 10/15/15 Page 25 of 56

26 > Malignant Hematology > Chronic Lymphocytic Leukemia (CLL) > Blood and Marrow Transplant (BMT) NCT Logan, Aaron A Randomized, Double- Blind, Placebo- Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)- Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) Age: 18+ Geraldine Pelle- Day; * Subject is a CMV- seropositive HCT recipient planning to undergo either of the Geraldine.pelle- day@ucsf.edu; 415- following: Sibling Donor Transplant pr Unrelated Donor Transplant * Subject has one of the following underlying diseases: Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Acute undifferentiated leukemia (AUL), Acute biphenotypic leukemia, Chronic myelogenous leukemia (CML), Chronic lymphocytic leukemia (CLL), A defined myelodysplastic syndrome(s) (MDS), Primary or secondary myelofibrosis, or Lymphoma (including Hodgkin's) NCT Logan, Aaron A Randomized, Double- Blind, Placebo- Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)- Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) Age: 18+ Geraldine Pelle- Day; * Subject is a CMV- seropositive HCT recipient planning to undergo either of the Geraldine.pelle- day@ucsf.edu; 415- following: Sibling Donor Transplant pr Unrelated Donor Transplant * Subject has one of the following underlying diseases: Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Acute undifferentiated leukemia (AUL), Acute biphenotypic leukemia, Chronic myelogenous leukemia (CML), Chronic lymphocytic leukemia (CLL), A defined myelodysplastic syndrome(s) (MDS), Primary or secondary myelofibrosis, or Lymphoma (including Hodgkin's) NCT Andreadis, Charalambos A Phase III, Randomised, Observer- Blind, Placebo- Controlled, Multicentre, Clinical Trial to Assess the Prophylactic Efficacy, Safety, and Immunogenicity of GSK Biologicals? Herpes Zoster ge/as01b Candidate Vaccine when Administered Intramuscularly on a Two- Dose Schedule to Adult Autologous Haematopoietic Stem Cell Transplant (HCT) Recipients Interventional Trials Open to Accrual as of 10/15/15 Page 26 of 56

27 12255 NCT Andreadis, Charalambos A Phase III, Randomised, Observer- Blind, Placebo- Controlled, Multicentre, Clinical Trial to Assess the Prophylactic Efficacy, Safety, and Immunogenicity of GSK Biologicals? Herpes Zoster ge/as01b Candidate Vaccine when Administered Intramuscularly on a Two- Dose Schedule to Adult Autologous Haematopoietic Stem Cell Transplant (HCT) Recipients > Malignant Hematology > Phase I > Lymphoma NCT Ai, Weiyun A Multicenter Phase I Dose- Finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax ) in Combination with Doxorubicin HCl Liposomal (Doxil ) for the of Adults with Relapsed or Refractory T- cell Lymphoma Age: 18+ * Biopsy- proven, measurable, Stage IB- IVB relapsed or refractory cutaneous T- cell lymphoma after 2 lines of skin- directed therapy or one prior line of systemic therapy * Disease free of prior malignancies for 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast. Patients with early stage of prostate cancer under clinical surveillance without therapy are eligible Alyson Cockerill; Alyson.Cockerill@ucsf.edu; Interventional Trials Open to Accrual as of 10/15/15 Page 27 of 56

28 > Malignant Hematology > Hodgkin Disease > Blood and Marrow Transplant (BMT) NCT Logan, Aaron A Randomized, Double- Blind, Placebo- Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)- Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) Age: 18+ Geraldine Pelle- Day; * Subject is a CMV- seropositive HCT recipient planning to undergo either of the Geraldine.pelle- day@ucsf.edu; 415- following: Sibling Donor Transplant pr Unrelated Donor Transplant * Subject has one of the following underlying diseases: Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Acute undifferentiated leukemia (AUL), Acute biphenotypic leukemia, Chronic myelogenous leukemia (CML), Chronic lymphocytic leukemia (CLL), A defined myelodysplastic syndrome(s) (MDS), Primary or secondary myelofibrosis, or Lymphoma (including Hodgkin's) > Malignant Hematology > Phase I > Lymphoma NCT Rubenstein, James A Phase I Study of Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma Age 18 and older * Tumors must be CD20+ on prior pathologic analysis * All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist. Alyson Cockerill; Alyson.Cockerill@ucsf.edu; Anna Winterkorn; winterkorna@ucsf.edu; Julia Yoshino; YoshinoJ@ucsf.edu; > Malignant Hematology > Acute Lymphoblastic Leukemia (ALL) > Blood and Marrow Transplant (BMT) NCT Logan, Aaron A Randomized, Double- Blind, Placebo- Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)- Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) Age: 18+ Geraldine Pelle- Day; * Subject is a CMV- seropositive HCT recipient planning to undergo either of the Geraldine.pelle- day@ucsf.edu; 415- following: Sibling Donor Transplant pr Unrelated Donor Transplant * Subject has one of the following underlying diseases: Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Acute undifferentiated leukemia (AUL), Acute biphenotypic leukemia, Chronic myelogenous leukemia (CML), Chronic lymphocytic leukemia (CLL), A defined myelodysplastic syndrome(s) (MDS), Primary or secondary myelofibrosis, or Lymphoma (including Hodgkin's) Interventional Trials Open to Accrual as of 10/15/15 Page 28 of 56